Option Chain

Adma Biologics Inc

ADMANASDAQ · USD

12.73USD-0.48 (-3.64%)

749

Adma Biologics Inc (ADMA) Option Chain

Adma Biologics Inc trades at $12.73, down 3.64%, with an IV Rank of 45.63%. This is average versus the past year, and the company carries a market cap of $2,959M in the Biotechnology industry. On the Nov 20, 2026 chain, the at the money $13.00 strike shows calls at $0.50 / $1.15 and puts at $0.45 / $1.35, both carrying about $0.73 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $11.00 calls, at 14,477 contracts, and the $13.00 puts, at 147, as of Nov 5, 2026.

Tracking the ADMA option chain helps you see every strike and expiry on Adma Biologics Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of ADMA options activity at a glance. Use our scanner to monitor the ADMA option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For ADMA stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where ADMA options are being actively traded, and where they are not.

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S.

CALLs									PUTs
Prob. OTM %	Open Interest	Volume	Extrinsic Value	Intrinsic Value	Bid	Ask	Strike	Moneyness %	Bid	Ask	Intrinsic Value	Extrinsic Value	Volume	Open Interest	Prob. OTM %
9.11	17,573	14,477	0.64	1.73	1.90	2.85	11.00	-16.73	—	0.50	0.00	0.50	1	62	90.89
25.00	610	474	0.79	0.73	1.25	1.80	12.00	-9.16	0.10	0.55	0.00	0.33	29	39	75.00
47.30	2,565	1,329	0.83	0.00	0.50	1.15	13.00	-1.59	0.45	1.35	0.27	0.63	147	7	52.70
68.93	619	189	0.55	0.00	—	0.55	14.00	+5.98	1.05	1.45	1.27	-0.02	70	8	31.07
84.54	989	882	0.10	0.00	0.05	0.15	15.00	+13.55	1.00	3.90	2.27	0.18	0	0	15.46

As of Nov 5, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

IndustryBiotechnology
SectorHealthcare
IV Rank45.63% Moderate
Market cap (M$)2,959
52 weeks high-35.43%
52 weeks low83.22%
Analyst recommendationBuy
1.75
Target price$18.00
46.66% above the current stock price
Dividend—
Payout ratio0.00%
Earnings date2026-11-04
P/E17.01
Future P/E14.88
EPS (ttm)0.78
EPS growth next 5 years19.38%

As of Nov 5, 2026

Browse all Option Chain tickers